News & Events

Read about our latest product developments and partnerships, industry advances and events.

Accera Enters into a Strategic Partnership and Exclusive Licensing Agreement with DuChemBio

July 12, 2017

BOULDER, Colo. and SEOUL, South Korea, July 11, 2017 – Accera, Inc. and DuChemBio Co. Ltd announced today that the companies have entered into a strategic partnership and exclusive licensing agreement whereby DuChemBio will obtain rights to develop, obtain regulatory approval and commercialize products in South Korea using Accera's medium chain triglyceride technology.

Accera, a leading CNS therapeutic company, is focused on pioneering novel therapeutic approaches to treat neurodegenerative diseases caused by metabolic deficiencies. Regional decreases in cerebral glucose metabolism are associated with aging and Alzheimer's disease (AD). Accera has developed proprietary technology based on medium chain triglycerides (MCTs) that provides the brain with ketone bodies, a natural alternative fuel to glucose. The company's lead program, AC-1204, is currently in Phase 3 clinical development as a drug for Alzheimer's patients.

Dementia including AD is a serious and growing problem in Korea. According to 2015 data reported by the Korean Health Insurance and Reimbursement Agency (HIRA), about 10% of the 6.5 million Koreans over the age of 65 have been diagnosed with dementia; 450,000 of these patients are suffering from AD. DuChemBio expects the number of AD patients to double by the year 2025. Mild cognitive impairment (MCI), considered a precursor stage of AD with some 50-75% of the patients developing AD within 5 years, represents a further, rapidly growing segment.

DuChemBio Korea has been active in the field of neurodegenerative diseases since 2012, primarily through manufacturing and commercialization of nuclear medicine diagnostics (molecular tracers for PET/CT imaging) for the early and precise diagnosis of Parkinson's and AD patients. Since 2015, DuChemBio works closely with Nuclear Medicine physicians and Neurologists to establish beta-amyloid PET imaging and has acquired market-leadership with 18F Florbetaben licensed from Piramal Imaging.

"The strategic partnership with Accera to develop and introduce medical products based on Accera's MCT technology in South Korea represents a major milestone in the evolution of DuChemBio towards a fully integrated healthcare company providing imaging and therapeutic solutions for this devastating brain disease," said JongWoo Kim, CEO and President of DuChemBio, stated at a signing ceremony held on June 26 in Seoul.

"The partnership with DuChemBio is an important milestone for Accera," said Dr. Charles Stacey, President and CEO of Accera. "Asia is a key market for Accera. We are very pleased to be establishing the first of our Asian partnerships with this leading group. Leveraging DuChemBio's expertise in diagnostics in AD and its relationships with neurologists and dementia experts in Korea will help Accera forward its novel approach to Alzheimer's disease in Asia."

BacktoTop